Insiders · Profile

Dulac Edward J III

EVP, Chief Financial Officer at Intellia Therapeutics · Chief Financial Officer at FATE THERAPEUTICS. Filing since 19 Aug 2021. CIK 0001821530

Company
Date
Role
Action
Shares
Amount
Of holding
22 Jul 2026
EVP, Chief Financial Officer
Sold at will
8,111
$91.25K
5.2%
2 Jul 2026
EVP, Chief Financial Officer
Sold on a plan
4,677
$84.19K
2.9%
5 Jan 2026
EVP, Chief Financial Officer
Sold at will
6,379
$58.75K
6.0%
23 Jul 2025
EVP, Chief Financial Officer
Sold at will
7,462
$104.62K
6.6%
4 Mar 2024
Chief Financial Officer
Sold on a plan
2,447
$19.01K
2.4%
29 Jan 2024
Chief Financial Officer
Sold on a plan
1,849
$9.25K
1.7%
9 Jan 2024
Chief Financial Officer
Sold at will
7,028
$30.71K
6.2%
2 Jan 2024
Chief Financial Officer
Sold on a plan
5,182
$18.97K
4.4%
18 Dec 2023
Chief Financial Officer
Sold on a plan
1,585
$5.55K
1.3%
18 Aug 2023
Chief Financial Officer
Sold at will
4,718
$13.21K
3.8%
5 Jul 2023
Chief Financial Officer
Sold on a plan
5,182
$25.03K
4.0%
10 Jan 2023
Chief Financial Officer
Sold, plan not stated
7,331
$38.41K
5.4%
18 Aug 2022
Chief Financial Officer
Sold, plan not stated
5,135
$153.05K
3.6%
11 Jan 2022
Chief Financial Officer
Sold, plan not stated
1,770
$85.76K
1.6%
20 Dec 2021
Chief Financial Officer
Sold, plan not stated
15,977
$958.62K
12.6%
28 Sep 2021
Chief Financial Officer
Sold, plan not stated
19,460
$1.22M
27.1%
19 Aug 2021
Chief Financial Officer
Sold, plan not stated
3,474
$306.60K
6.0%
17 decisions on file.